VIDEO: First-line anti-EGF vs. anti-VEGF in certain patients with colorectal cancer
Click Here to Manage Email Alerts
In this video, Howard S. Hochster, MD, FACP, discusses a late-breaking abstract on the phase 3 PARADIGM trial, which looked at panitumumab vs. bevacizumab as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.
Both panitumumab (Vectibix, Amgen) and bevacizumab (Avastin, Genentech) were given with modified FOLFOX6 chemotherapy.
"We have done a number of studies that have led us to the realization that there may be a difference between giving an anti-[epidermal growth factor] drug or an anti-VEGF drug in this setting," Hochester, associate director for clinical research and director of GI Oncology at Rutgers Cancer Institute, said.
Hochester explained that the study appears to show that giving the anti-EGF drug panitumumab results in better response rates and disease control rates than bevacizumab.
“It looks like it remains unclear why using anti-EGF first does not translate into higher PFS but longer survival, and that is something we still need to work on " Hochester said.
Collapse
Read more about
Click Here to Manage Email Alerts